Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Ipilimumab in Advanced Mucosal or Acral Lentiginous Melanoma
NCT02978443Phase 2Terminated
- Sponsor
- Georgetown University
- Start
- Jul 2017
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in mucosal melanoma (MM) and acral lentiginous melanoma (ALM), sponsored by Georgetown University. Primary endpoint: Objective Response Rate With Mucosal Melanoma at 24 months. Started Jul 2017; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
mucosal melanoma (MM)acral lentiginous melanoma (ALM)
Beyond the preview
Go deeper on NCT02978443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02978443.